Skip to main content

Table 2 Prevalence of comorbidities: adults ≥45 with and without physician-diagnosed COPD: NHANES 1999–2008

From: The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008

Conditions Without COPD With COPD P-valuec
(n = 14,828)a (n = 995)b
Diseases
CHF, %, (95% CI) 3.9 (3.6–4.3) 12.1 (9.8–14.8) <.0001
CHD, %, (95% CI) 6.1 (5.5–6.7) 12.7 (10.5–15.3) <.0001
HTN, %, (95% CI) 52.2 (50.7–53.7) 60.4 (55.8–64.8) 0.0006
High cholesterol, %, (95% CI) 41.3 (39.9–42.6) 47.6 (43.0–52.2) 0.0096
CVA, %, (95% CI) 4.6 (4.2–5.0) 8.9 (7.0–11.1) <.0001
Diabetes, %, (95% CI) 12.8 (12.1–13.7) 16.3 (13.3–19.8) 0.0184
Osteoporosis, %, (95% CI) 8.5 (7.8–9.2) 16.9 (13.7–20.7) <.0001
Arthritis, %, (95% CI) 36.9 (35.6–38.2) 54.6 (49.8–59.3) <.0001
Cancer, %, (95% CI) 9.9 (9.3–10.6) 16.5 (14.2–19.0) <.0001
Depression, %, (95% CI) 12.5 (11.8–13.3) 20.6 (17.1–24.6) <.0001
Anxiety, %, (95% CI) 3.8 (3.3–4.3) 8.6 (6.6–11.1) <.0001
Clinical Factors
Dizziness/Balance Problems, %, (95% CI)d 23.8 (22.4–25.4) 41.1 (36.3–46.1) <.0001
Obesity, %, (95% CI) 33.5 (32.0–35.1) 40.3 (36.4–44.4) 0.0013
Urinary Incontinence, %, (95% CI) 27.3 (26.1–28.7) 34.9 (29.6–40.5) 0.0048
Anemia, %, (95% CI) 6.2 (5.5–7.1) 9.3 (7.1–12.0) 0.0030
Low GFR, %, (95% CI) 10.5 (9.7–11.2) 16.2 (13.3–19.5) <.0001
>4 meds, %, (95% CI) 32.1 (30.5–33.8) 51.8 (46.2–57.2) 0.0022
Frailty, %, (95% CI) 3.1 (2.7–3.6) 9.5 (7.0–12.8) <.0001
Health Status Factors
Memory problems, %, (95% CI) 8.8 (8.1–9.5) 18.5 (14.9–22.7) <.0001
Mobility difficulty, %, (95% CI) 32.5 (30.7–34.4) 55.6 (50.6–60.5) <.0001
Hearing impairment, %, (95% CI) 8.3 (7.7–8.9) 12.1 (9.8–14.9) 0.0008
Visual impairment, %, (95% CI) 9.6 (9.0–10.3) 14.0 (12.0–16.2) <.0001
All Conditions
> = 1 comorbid condition, %, (95% CI) 87.7 (86.4–88.8) 96.4 (94.3–97.8) <.0001
  1. a Represents ~100 million noninstitutionalized US civilians.
  2. b Represents ~10 million noninstitutionalized US civilians.
  3. c The Bonferroni-corrected significance level, α, is 0.0011.
  4. d Only assessed 1999–2004.